MedTrace Logo

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2018-07-13

No results posted yet for this study

Summary

The purpose of the study is to study the effects of BMS-955176 on the single-dose PK parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin

Conditions

  • HIV Infections

Interventions

DRUG

CYP and transporter probe substrates

Cocktail of CYP (cytochrome P450) and transporter probe substrates

DRUG

BMS-955176

BMS-955176

DRUG

BMS-955176 plus CYP and transporter probe substrates

BMS-955176 plus the cocktail of CYP and transporter probe substrates

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-09
Primary Completion
2015-12-23
Completion
2015-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578277 on ClinicalTrials.gov